Blåblokkerende briller som tilleggsbehandling ved mani. Effekt på søvn målt med aktigrafi

Bedring av søvn er et sentralt behandlingsmål for pasienter i manisk tilstand. Blåblokkerende (BB) briller har vist god effekt som tilleggsbehandling ved behandling av mani. I denne studien har forskere fra Universitetet i Bergen, Helse Fonna HF, Haukeland universitetssykehus, og Stavanger universitetssykehus undersøkt effekten av BB-briller som tilleggsbehandling for maniske pasienter sammenlignet med placebo og effekten dette har på søvn målt med aktigrafi. Innlagte pasienter med bipolar lidelse i en manisk fase brukte BB-briller eller placebo briller (klart glass) fra kl. 18:00 til 08:00 syv netter på rad. Søvn og våkenhet ble målt med aktigrafi. Resultatene viste at BB-gruppen fikk mindre hypnotika og viste betydelig høyere søvneffektivitet sammenlignet med placebogruppen. Studien viser at tilleggsbehandling med BB-briller ser ut til å være nyttige for å bedre søvn for maniske pasienter innlagt i sykehus.

Blue-blocking glasses as additive treatment for mania: Effects on actigraphy-derived sleep parameters.

Studien er publisert i Journal of Sleep Research

Tone Elise Gjøtterud Henriksen, Janne Grønli, Jørg Assmus, Ole Bernt Fasmer, Helle Schøyen, Ieva Leskauskaite, Jeanette Bjørke-Bertheussen, Kjersti Ytrehus, Anders Lund

Improvement of sleep is a central treatment goal for patients in a manic state. Blue-blocking (BB) glasses as adjunctive treatment hasten overall recovery from mania. This method is an evolvement from dark therapy and builds on the discovery of the blue-light-sensitive retinal ganglion cell that signals daytime to the brain. We report effects of adjunctive BB glasses on actigraphy-derived sleep parameters for manic inpatients as compared to placebo. Hospitalized patients with bipolar disorder in a manic state aged 18-70 years were recruited from five clinics in Norway from February 2012 to February 2015. The participants were randomly allocated to wearing BB glasses or placebo (clear glasses) as an adjunctive treatment from 18:00 to 08:00 hours for seven consecutive nights. Sleep and wake were monitored by actigraphy. From 32 eligible patients, 10 patients in each group qualified for the group analyses. The BB group's mean sleep efficiency was significantly higher at night 5 as compared to the placebo group (92.6% vs. 83.1%, p = .027). The 95% confidence interval (CI) was 89.4%-95.8% in the BB group and 75.9%-90.3% in the placebo group. There were fewer nights of interrupted sleep in the BB group: 29.6% versus 43.8% in the placebo group. The BB group received less-intensive sleep-promoting pharmacological treatment and showed significantly higher sleep efficiency and more consolidated sleep as compared to the placebo group. Our findings suggest sleep-promoting effects through deactivating mechanisms. Adjunctive BB glasses seem to be useful for improving sleep for manic patients in the hospital setting.